Nisha Mohindra is an Oncology physician affiliated with Northwestern University. OpenAlex indexes 121 publications with 4,596 citations (h-index 26); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
675 N Saint Clair
Suite 2100
Chicago, IL 606113549
Telephone
312-695-0990Registry record last updated 24 Sept 2015.
Clinical trials
- Carboplatin/Nab-Paclitaxel and Pembrolizumab in NSCLC
Sponsor: Nisha Mohindra, MD
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
16 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- JAZZ PHARMACEUTICALS INC.Program year20257 payments
- Regeneron Healthcare Solutions, Inc.Program year20254 payments
- Merck Sharp & Dohme LLCProgram year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Blood & clotting
45.7%Parenteral Iron Replacement24%Iron sucrose100%Part B, office-administered≥17 patientsErythropoiesis-stimulating Agent21.7%Darbepoetin alfa100%Part B, office-administered≥11 patients+ 1 more class in this area
Metabolism & gastrointestinal
37.2%Other antiemetics34.4%Fosaprepitant100%Part B, office-administered≥20 patientsSerotonin-3 Receptor Antagonist2.8%Palonosetron hcl96%Ondansetron Odt5%Part D + Part B≥22 patientsCancer & immunology
12.9%Folate Analog Metabolic Inhibitor11.6%Pemetrexed100%Part B, office-administered≥12 patientsPlatinum-based Drug0.9%Carboplatin100%Part B, office-administered≥15 patients+ 1 more class in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- NCCN Guidelines® Insights: Management of Immunotherapy-Related Toxicities, Version 2.2024
Journal of the National Comprehensive Cancer Network
2024
Similar KOLs
Other experts from the same institution or the same specialty.
Clyde Yancy, MD
Northwestern University
Philip Greenland, MD
Northwestern University
Peter Kahrilas, MD
Northwestern University
Philip Gorelick, MD
Northwestern University
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”